NCT00081250CompletedPhase 3
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Alliance for Clinical Trials in Oncology220 sites in 1 country300 target enrollmentStarted: December 1, 2004Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 300
- Locations
- 220
- Primary Endpoint
- Percentage of patients who gain weight over 1 month
Study Overview
Brief Summary
RATIONALE: It is not yet known whether the supplement creatine is effective in increasing weight and improving appetite and quality of life in patients who have cancer.
PURPOSE: This randomized phase III trial is studying how well creatine works in increasing weight and improving appetite and quality of life in patients with weight loss caused by cancer.
Detailed Description
OBJECTIVES:
- Compare weight-gain effects of creatine vs placebo in patients with cancer-associated weight loss and/or anorexia.
- Determine the effect of these regimens on quality of life in these patients.
- Compare the toxic effects of these regimens in these patients.
- Compare survival rates of patients treated with these regimens.
OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are stratified according to primary cancer type (lung vs gastrointestinal vs other), weight loss severity (< 10 lbs vs ≥10 lbs), age (< 50 years vs ≥ 50 years), planned concurrent chemotherapy (yes vs no), gender, and prognosis. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral creatine daily.
- Arm II: Patients receive oral placebo daily. In both arms, treatment continues in the absence of unacceptable toxicity as long as treatment is considered beneficial.
Patients are followed every 6 months for up to 5 years.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Supportive Care
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically confirmed cancer other than primary brain cancer
- •Considered incurable with available therapies
- •History of weight loss ≥ 5 lbs in 2 months or fewer AND/OR estimated intake of < 20 cal/kg daily
- •Determination by attending physician that weight gain would benefit patient
- •Perception by patient that weight loss is a problem
- •No symptomatic or untreated brain metastases
- •No clinical evidence of ascites
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status
- •Life expectancy
- •At least 3 months
- •Creatinine normal
- •Cardiovascular
- •No poorly controlled congestive heart failure
- •No poorly controlled hypertension
- •Able to reliably receive oral medication
- •Must be alert and mentally competent
- •No known obstruction of the alimentary tract, malabsorption, or intractable vomiting
- •No diabetes that is controlled by insulin
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •PRIOR CONCURRENT THERAPY:
- •Chemotherapy
- •Concurrent chemotherapy allowed
- •Endocrine therapy
- •No other concurrent adrenal corticosteroids, androgens, or progestational agents within 30 days after study entry
- •Concurrent short-term dexamethasone for chemotherapy-associated emesis is allowed
- •Concurrent inhalant, topical, or optical steroids allowed
- •Radiotherapy
- •No concurrent radiotherapy to the bowel or stomach
- •Other concurrent radiotherapy allowed
- •No prior creatine use
- •No concurrent tube feedings or parenteral nutrition
Exclusion Criteria
- Not provided
Arms & Interventions
Arm II
Placebo Comparator
Patients receive oral placebo daily.
Intervention: placebo (Other)
Arm I
Experimental
Patients receive oral creatine daily.
Intervention: creatine monohydrate (Dietary Supplement)
Outcomes
Primary Outcomes
Percentage of patients who gain weight over 1 month
Time Frame: 1 month
Secondary Outcomes
- Overall survival(Up to 5 years)
- Percentage of patients who manifest weight stability (i.e., weight within 5% of baseline) at 1 month(1 month)
- Percentage of patients who manifest stability in appetite(Up to 5 years)
- Incidence of treatment-related toxicity(Up to 5 years)
- Quality of life(Up to 5 years)
Investigators
Study Sites (220)
Loading locations...
Similar Trials
Unknown
Not Applicable
Creatine on Bone Mass in Postmenopausal WomenPostmenopausal WomenNCT01472393University of Sao Paulo200
Withdrawn
Phase 2
Combined Cytidine and Creatine-containing Drug in the Treatment of the Bipolar DepressionDepression, BipolarNCT02625779Ewha Womans University Mokdong Hospital
Withdrawn
Not Applicable
Influence of Creatine Monohydrate Supplementation on Androgens and Global Hair AssessmentsDihydrotestosteroneTestosteroneHair LossNCT04298840Texas Tech University
Terminated
Phase 4
Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in FemalesMajor Depressive DisorderNCT02922725Brent Michael Kious, MD, PhD32
Completed
Phase 3
Effects of Creatine Supplementation on Muscle Mass and Function Among Older Women Subjected to Resistance TrainingMuscle WeaknessNCT02188849University of Chile50